Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

550.54 +0.41 (+0.07%)
Official Closing Price Updated: 7:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Why Shares of Ventyx Biosciences Rose Monday
The company has several promising autoimmune therapies. 
Via The Motley Fool
Eli Lilly Could Be Making The Next Ozempic, but Should You Buy the Stock?
Clinical data suggests that a powerful candidate is advancing through its pipeline. 
Via The Motley Fool
Barron's Weekend Stock Picks: Eli Lilly, Activision And What's Next For Tesla
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Eli Lilly Unusual Options Activity For June 30
Via Benzinga
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
Health Care Company Eli Lilly Announces Acquisition of Sigilon Therapeutics
Via Benzinga
Eli Lilly Is A Potential Triple Threat
Eli Lilly reported stunning new efficacy data in obesity but there is a potential cardiac signal that needs to be watched. 
Via Talk Markets
Better Artificial Intelligence Stock: GSK or Eli Lilly?
Which of these AI-powered drugmakers is the better buy right now? 
Via The Motley Fool
The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023
Investors looking to buy low and eventually sell high would be smart to take a position with one or more of these pharma stocks. 
Via InvestorPlace
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
Madrigal is working on gaining FDA approval for what could be the first NASH treatment. 
Via Investor's Business Daily
3 Dividend Stocks That Have Insiders Running for the Exit
One measurement used to find dividend stocks to avoid is the level of insider selling; here are three stocks that fit that description 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023
If you dig deep enough, you’ll find some undervalued biotech stocks with substantial catalysts straight ahead. 
Via InvestorPlace
Sigilon Therapeutics Scores Eli Lilly Buyout And Skyrockets More Than 500%
Eli Lilly is getting deeper into type 1 diabetes treatment with this buyout. 
Via Investor's Business Daily
Sigilon Therapeutics Shares Are Shooting Higher Today - What's Going On
Sigilon Therapeutics Inc (NASDAQ: SGTX) shares are skyrocketing after Eli Lilly And Co (NYSE: LLY) agreed to acquire the company for a purchase price of $14.92 per share in cash (an aggregate of  
Via Benzinga
Ozempic Overshadowed As Eli Lilly's Retatrutide Promises Unprecedented Weight Loss: Bloomberg
Via Benzinga
$100 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Why Eli Lilly Stock Briefly Popped Today
Investors cheered the drugmaker's latest mid-stage results in obesity care. 
Via The Motley Fool
Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?
Sigilon Therapeutics (SGTX) stock is rocketing higher on Thursday morning after Eli Lilly (LLY) agrees to acquire the company. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today! 
Via InvestorPlace
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was... 
Via Benzinga
Why Viking Therapeutics Is Plunging Today
The biotech's shares are being negatively impacted today by mid-stage data for a competing weight loss drug. 
Via The Motley Fool
Check Out What Whales Are Doing With LLY
Via Benzinga
NeuroBo Pharma Says Its Weight Loss Candidate Outperforms Major Competitors in Preclinical Obesity Study
NeuroBo Pharmaceuticals Inc (NASDAQ: NRBO) says its DA-1726, a novel oxyntomodulin analog functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, had been shown to elicit... 
Via Benzinga
Eli Lilly Sets New Bar In Weight Loss And Nears Record High; Novo Nordisk Slips
Eli Lilly is competing against Novo Nordisk for dominance in the obesity treatment market. 
Via Investor's Business Daily
Next-Gen Weight-Loss Drugs Set To Up The Game From Ozempic And Mounjaro: WSJ
Via Benzinga
Move Over, Ozempic: Eli Lilly's Retatrutide Is The New Weight Loss Champion
Via Benzinga
Why Viking Therapeutics Stock Is Crashing Today
Investors seem concerned about the company's competitive positioning in weight loss. 
Via The Motley Fool
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other... 
Via Benzinga
Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Vs. Novo Nordisk, Eli Lilly
The company is discontinuing what may have been its best shot due to a side effect. 
Via Investor's Business Daily
Wall Street Hungry For Weight-Loss Pill As Pharma Giants Rush To Get Rid Of Shots: WSJ
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.